Coronavirus Treatment Drugs Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-05-04　·　151 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 24.8 Bn
2033 年預估規模: USD 62 Bn
年複合成長率 CAGR: 13.3%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-05-04頁數 151報告編號 CMI4312

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Coronavirus Treatment Drugs Market, By Drug Class (Corticosteroids, Anti-viral drugs, Monoclonal Antibodies, Kinase Inhibitors, Others), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

The coronavirus treatment drugs comprises therapeutics which are used for treatment of the novel coronavirus. There are various drug classes such as corticosteroids, anti-viral, monoclonal antibodies, Kinase inhibitors which can be used for treatment of the coronavirus. The coronavirus is generally treated depending on severity of symptoms such as severe, moderate and mild. The common symptoms of coronavirus are cold, fever, breathlessness, headache, and stomach pain. Market Dynamics Key players are focusing on obtaining product approvals in order to strengthen their position in the global coronavirus treatment drugs market. For instance, in June 2020, Glenmark Pharmaceuticals Limited, a pharmaceutical company in India, launched the first orally administered tablet, Fabiflu, for the treatment of patients suffering from mild and moderate symptoms of COVID-19. Fabiflu is available as a 200 mg tablet, has been priced at US$ 1 per tablet. A strip of 34 tablets will cost US$ 47.55 to the patients in India. Furthermore, key companies are focusing on inorganic strategies such agreements in order to strengthen their position in the global coronavirus treatments drugs market. For instance, in September 2020, Dr Reddy's Laboratories, an Indian pharmaceutical company, announced the launch of Remdesivir under the brand name, Redyx, for the Indian market. The launch of Redyx for treatment for COVID-19 is because of licensing agreement of Dr Reddy Laboratories with Gilead Sciences Inc. which grants Dr Reddy's Laboratories the right to register, manufacture and sell Remdesivir, as a potential treatment for COVID-19 in 127 countries including India. Key features of the study • This report studies the current scenario as well as the future potential of the global coronavirus treatment drugs market. The market for coronavirus treatment drugs is segmented on the basis of drug class, route of administration, distribution channel, and region. • This report provides in-depth analysis of the global coronavirus treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2026-2033) • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by leading players. • It profiles leading players in the global coronavirus treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans. • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics • The global coronavirus treatment drugs market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts • Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global coronavirus treatment drugs market. Market Segmentation • By Drug Class (Revenue, USD Bn, 2021-2033) o Corticosteroids o Anti-viral drugs o Monoclonal Antibodies o Kinase Inhibitors o Others • By Route of Administration (Revenue, USD Bn, 2021-2033) o Oral o Intravenous • By Distribution Channel (Revenue, USD Bn, 2021-2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • By Region (Revenue, USD Bn, 2021-2033) o North America  U.S.  Canada o Latin America  Brazil  Mexico  Argentina  Rest of Latin America o Europe  Germany  U.K.  France  Italy  Spain  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC  Israel  Rest of Middle East o Africa  South Africa  Central Africa  North Africa • Key Players o Serum Institute of India o Pfizer Inc. o AstraZeneca plc. o Bharat Biotech International Limited o Cadila Healthcare Limited o Johnson & Johnson o Moderna o GlaxoSmithKline plc. o CanSino Biologics o Sinovac Biotech o Novavax, Inc. o Glenmark Pharmaceuticals Limited o Merck & Co., Inc. o Reddy's Laboratories

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Overview o Report Description  Market Definition and Scope o Executive Summary  Global Coronavirus Treatment Drugs Market, By Drug Class  Global Coronavirus Treatment Drugs Market, By Route of Administration  Global Coronavirus Treatment Drugs Market, By Distribution Channel  Global Coronavirus Treatment Drugs Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trend 4. Global Coronavirus Treatment Drugs Market, By Drug Class, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Corticosteroids  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Anti-viral drugs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Monoclonal Antibodies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Kinase Inhibitors  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 5. Global Coronavirus Treatment Drugs Market, By Route of Administration, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Oral  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Intravenous  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 6. Global Coronavirus Treatment Drugs Market, By Distribution Channel, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 7. Global Coronavirus Treatment Drugs Market, By Region, 2021 - 2033, Value (USD Bn) o Introduction  Market Share (%) Analysis, 2026 & 2033, Value (USD Bn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o South Africa o North Africa o Central Africa 8. Competitive Landscape o Serum Institute of India  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Pfizer Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AstraZeneca plc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Bharat Biotech International Limited  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Cadila Healthcare Limited  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Johnson & Johnson  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Moderna  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o GlaxoSmithKline plc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o CanSino Biologics  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Sinovac Biotech  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Novavax, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Glenmark Pharmaceuticals Limited  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Dr. Reddy's Laboratories  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Merck & Co., Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 9. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 10. References and Research Methodology o References o Research Methodology o About us

提及公司

Serum Institute of IndiaPfizer Inc.AstraZeneca plc.Bharat Biotech International LimitedCadila Healthcare LimitedJohnson & JohnsonModernaGlaxoSmithKline plc.CanSino BiologicsSinovac BiotechNovavax, Inc.Glenmark Pharmaceuticals LimitedMerck & Co., Inc.Reddy's Laboratories

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們